Insilico and TaiGen Advance AI-Derived CKD Anemia Candidate to Phase I

The transition of ISM4808 from an AI-generated lead to a clinical-stage asset represents a significant milestone in the evolution of computational drug discovery. Insilico Medicine and TaiGen Biopharmaceuticals have officially commenced human dosing in a Phase I clinical trial, testing a novel Prolyl Hydroxylase Domain (PHD) inhibitor designed to treat anemia associated with Chronic Kidney Disease (CKD). This development is not merely a pipeline advancement for TaiGen; it serves as a high-stakes validation of the 'discovery-as-a-service' model, where AI-native firms provide optimized candidates to established clinical partners for downstream development.

CKD anemia is a pervasive and debilitating condition characterized by the kidneys' inability to produce sufficient erythropoietin (EPO), leading to chronic fatigue and increased cardiovascular risk. For decades, the standard of care has relied on Erythropoiesis-Stimulating Agents (ESAs), which require frequent injections and have been linked to safety concerns, including hypertension and thrombosis. ISM4808 belongs to a newer class of oral medications known as HIF-PH inhibitors. These drugs work by stabilizing Hypoxia-Inducible Factor (HIF), essentially tricking the body into thinking it is at a high altitude, which naturally stimulates the production of EPO and improves iron absorption.

“

Insilico Medicine and TaiGen Biopharmaceuticals have officially commenced human dosing in a Phase I clinical trial, testing a novel Prolyl Hydroxylase Domain (PHD) inhibitor designed to treat anemia associated with Chronic Kidney Disease (CKD).

What differentiates ISM4808 from existing competitors—such as GSK’s Jesduvroq (daprodustat) or Akebia’s Vafseo (vadadustat)—is its origin. Insilico Medicine utilized its proprietary Pharma.AI platform to design the molecule from scratch, optimizing for high potency and a highly selective safety profile. The goal of using AI in this context was to bypass the traditional trial-and-error of medicinal chemistry, potentially resulting in a molecule that avoids the off-target effects that have complicated the regulatory path for earlier HIF-PH inhibitors in the United States. By achieving first-in-human dosing, the partners are now moving to prove that these AI-driven design advantages translate into superior pharmacokinetic and safety data in humans.